Cut-off-independent tumour marker evaluation using ROC approximation

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4305-4310

  Bitterlich, Norman ^a   Schneider, Joachim ^b  

^a Medizin und Service GmbH   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Cut off values; Lung cancer; Receiver operating characteristic (ROC) curves; Tumour markers

Indexed keywords

CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASBESTOSIS; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PNEUMONIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SILICOSIS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 37548998937     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bitterlich N: Tumormarker-Profilauswertung - und aus Daten wird Information. J Lab Med 29: 108-112, 2005.
2. Bitterlich N and Schneider J: Decision guarantee in tumour marker analysis: a cut-off independent assessment. Anticancer Res 27: 1933-1940, 2007.
3. Parker JE: Radiological criteria: the use of chest imaging techniques in asbestos-related diseases. In: Proceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer. People and Work. Finish Institute of Occupational Health, Helsinki, Finland, Research Reports 14: 28-40, 1997.
4. Bitterlich N, Schneider J and Lindner E: Roc curves-can differences in AUC be significant? Int J Biol Markers 18: 227-229, 2003.
5. Guangqin MA and Hall WJ: Confidence bands for receiver operating characteristics curves. Med Decis Making 13: 191-197, 1993.
6. Schäfer H: Efficient confidence bounds for ROC curves. Stat Med 13: 1551-1561, 1994.
7. Kraus T and Raithel HJ: Frühdiagnostik asbeststaubverursachter Erkrankungen. Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, Sankt Augustin, pp. 1-145, 1998.
8. Raithel HJ and Lehnert G: Aussagemöglichkeiten moderner computertomographischer Untersuchungsverfahren bei der Diagnose berufsbedingter Staublungenerkrankungen. Arbeitsmed Sozialmed Präventivmed 25: 144-150, 1990.
9. Vehmas T, Kivisaari L, Zitting A, Mattson K, Nordman H and Huuskonen M: Computed tomography (CT) and high resolution CT for the early diagnosis of lung and pleural disease in workers exposed to asbestos: Finnish experiences. In: Proceedings of an International Expert Meeting on New Advances in Radiology and Screening of Asbestos-related Diseases. Helsinki, Finnish Institute of Occupational Health. People and Work Research Reports 36: 53-56, 2000.
10. Marek W, Krampe S, Dickgreber NJ, Nielsen L, Muti A, Khanavkar B, Müller KM, Atay Z, Topalidis T and Nakhosteen JA: Automatisierte quantitative Image-Zytometrie bronchialer Spülungen bei Verdacht auf ein Bronchialkarzinom: Vergleich mit Zytologie, Histologie und Enddiagnose. Atemw-Lungenkrkh 24: 316-319, 1998.
11. Böcking A, Biesterfeld S, Chatelain R, Gien-Gerlach G and Esser E: Diagnosis of bronchial carcinoma on sections of paraffin-embedded sputum. Sensitivity and specificity of an alternative to routine cytology. Acta Cytol 36: 37-47, 1992.
12. Schiller JH: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61: 3-13, 2001.
13. Henschke CI, McCauley DI, Yankelvitz DF, Naidich DP, McGuiness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK and Smith JP: Early lung cancer action project: overall design and findings from baseline screening. Lancet 354: 99-105, 1999.
14. Schneider J: Tumor markers in detection of lung cancer. Advances Clin Chem 42: 1-41, 2006.
15. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K and Eigenbrodt E: Comparison of the tumour markers Tumor M2-PK, CEA, CYFRA-21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
16. Molina R, Agusti C, Mane JM, Filella X, Jo J, Joseph J, Gimenez N, Estape J and Ballesta AM: CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 9: 96-101, 1994.
17. Ebert W, Hoppe M, Muley T and Drings P: Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP, CEA and NSE. Anticancer Res 17: 2875-2878, 1997.
18. Stieber P, Dienemann H, Hasholzner U, Müller C, Poley S, Hofmann K and Fateh-Moghadam A: Comparison of cytokeratinfragment 19 (CYFRA 21-1), tissue polypeptide specific antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 31: 689-694, 1993.
19. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J and Viladiu P: Tumor marker (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003.
20. Moro D, Villemain D, Vuillez JP, Delord CA and Brambilla C: CEA, CYFRA 21-1 and SCC in non-small cell lung cancer. Lung Cancer 13: 169-176, 1995.
21. Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K and Okura H: Preliminary evaluation of the new tumour marker CYFRA 21-1 in lung cancer patients. Jpn J Clin Oncol 24: 263-268, 1996.
22. Lombardi C, Tassi GF, Pizzicolo G and Donato F: Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 97: 639-644, 1990.